Cytokinetics Previews Upcoming Phase 3 ACACIA-HCM Readout, Highlights Myqorzo Launch Traction

Biotech firm provides updates on its cardiac myosin inhibitor pipeline at Citi conference

Mar. 15, 2026 at 4:05am

Got story updates? Submit your updates here. ›

Cytokinetics (NASDAQ:CYTK) used its presentation at Citi's Life Sciences Conference to highlight the recent U.S. approval of its first drug, Myqorzo, and to preview an upcoming Phase 3 readout in non-obstructive hypertrophic cardiomyopathy (NHCM) that management described as a major near-term catalyst.

Why it matters

Cytokinetics is entering an established market for obstructive hypertrophic cardiomyopathy (OHCM) with Myqorzo, but sees a significant opportunity in the potentially larger NHCM segment if its ACACIA-HCM Phase 3 trial is successful. The company believes it could be alone in the NHCM market if approved, while still competing in the existing OHCM space.

The details

CEO Robert Blum said Cytokinetics expects clinical trial results in the second quarter from ACACIA-HCM, a pivotal Phase 3 study evaluating Myqorzo in NHCM. Myqorzo is already approved in OHCM, and Blum framed the NHCM opportunity as roughly comparable in size to the obstructive market. The company believes there are at least 100,000 OHCM patients in the U.S. who could be eligible for Myqorzo treatment, and a 'similar number' of NHCM patients potentially available. Chief Medical Officer Fady Malik described the similarities and differences between obstructive and non-obstructive disease, noting both share common underlying pathology but NHCM lacks the left ventricular outflow tract gradient that is reduced in obstructive disease, which could 'mute' treatment effects on exercise performance.

  • Cytokinetics expects clinical trial results from the ACACIA-HCM Phase 3 study in the second quarter of 2026.
  • Myqorzo was launched in the U.S. in January 2026, with product in channel in the third week of the month.

The players

Cytokinetics

A late-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics that modulate muscle function.

Robert Blum

CEO of Cytokinetics.

Fady Malik

Chief Medical Officer of Cytokinetics.

Myqorzo

Cytokinetics' first approved drug, a cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy.

Camzyos

A cardiac myosin inhibitor developed by Bristol Myers Squibb for the treatment of hypertrophic cardiomyopathy.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.